The impact of chronic hepatitis B treatment on hepatocellular carcinoma incidence was evaluated in a long-term analysis of the Gilead drug. More: Vemlidy tackles hep B in late-stage trials Source: News
read moreThe cleaning procedures are so poor at a Zydus Cadila plant in India that the FDA says a sampling found 10 different tablet products that were cross-contaminated with API residue from another drug during production. More: FDA orders Cadila to
read moreJ&J is appealing a $572 million opioid verdict in Oklahoma, but as that process plays out, state politicians contend the drugmaker should be on the line for future abatement costs. Lawyers for the company say the argument is “unnecessary, redundant,
read moreAbbott Laboratories chief Miles White will shed his CEO title next year after a 21-year run at the company’s helm—and several major transformations to his credit. Taking his place will be Robert Ford, whom White elevated to president and chief
read moreAfter the FDA issued a global recall last year of “sartan”-based drugs contaminated with a possible carcinogen, there’s been plenty of blame to pass around. The most recent recipient of regulators’ ire is Mylan, which was knocked with a warning
read moreMerck & Co.’s $1.2 billion restructuring of its manufacturing operations has fallen on a site in France, where more than 200 manufacturing and R&D jobs will be swept away and the site put up for sale. More: Merck cutting more
read more© 1994 - 2026 B.M. Pharmaceuticals